Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNKS | O95271 | 15/20 | 0.75 |
| ▸ | PARP1 | P09874 | 5/20 | 0.75 |
| ▸ | CHKA | P35790 | 2/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | NCF1 | P14598 | 1/20 | 0.46 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.46 |
| ▸ | BTK | Q06187 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16578845 | 0.88 | TNKS (0.72) | TNKSPARP1CHKA | |
| SCHEMBL16625114 | 0.86 | TNKS (0.80) | TNKSPARP1CHKA | |
| SCHEMBL16625111 | 0.86 | TNKS (1.00) | TNKSPARP1CHKABTK | |
| SCHEMBL16578959 | 0.85 | TNKS (0.78) | TNKSPARP1CHKABTK | |
| SCHEMBL16578831 | 0.84 | TNKS (0.67) | TNKSPARP1BTK | |
| SCHEMBL16578830 | 0.84 | TNKS (0.67) | TNKSPARP1BTK | |
| SCHEMBL16578745 | 0.82 | TNKS (0.55) | TNKSPARP1 | |
| SCHEMBL16569773 | 0.82 | TNKS (0.74) | TNKSPARP1CHKABTK | |
| SCHEMBL16625136 | 0.82 | TNKS (0.92) | TNKSPARP1CHKACA2NCF1 | |
| SCHEMBL16625118 | 0.82 | TNKS (0.74) | TNKSPARP1BTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3044221-B1 | 3-ARYL-5-SUBSTITUTED-ISOQUINOLIN-1-ONE COMPOUNDS AND THEIR THERAPEUTIC USE | INST OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (THE) (GB) | 2018-02-21 | — | — | EP | disclosed |
| EP-3044221-B1 | 3-ARYL-5-SUBSTITUTED-ISOQUINOLIN-1-ONE COMPOUNDS AND THEIR THERAPEUTIC USE | INST OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (THE) (GB) | 2018-02-21 | — | — | EP | disclosed |
| US-9611223-B2 | 3-aryl-5-substituted-isoquinolin-1-one compounds and their therapeutic use | INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (THE) (GB) | 2017-04-04 | — | — | US | disclosed |
| US-9611223-B2 | 3-aryl-5-substituted-isoquinolin-1-one compounds and their therapeutic use | INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (THE) (GB) | 2017-04-04 | — | — | US | disclosed |
| US-9611223-B2 | 3-aryl-5-substituted-isoquinolin-1-one compounds and their therapeutic use | INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (THE) (GB) | 2017-04-04 | — | — | US | disclosed |
| US-20160221953-A1 | 3-ARYL-5-SUBSTITUTED-ISOQUINOLIN-1-ONE COMPOUNDS AND THEIR THERAPEUTIC USE | INSTITUTE OF CANCER RESEARCH ROYAL CANCER HOSPITAL (THE) (GB) | 2016-08-04 | — | — | US | disclosed |
| US-20160221953-A1 | 3-ARYL-5-SUBSTITUTED-ISOQUINOLIN-1-ONE COMPOUNDS AND THEIR THERAPEUTIC USE | INSTITUTE OF CANCER RESEARCH ROYAL CANCER HOSPITAL (THE) (GB) | 2016-08-04 | — | — | US | disclosed |
| US-20160221953-A1 | 3-ARYL-5-SUBSTITUTED-ISOQUINOLIN-1-ONE COMPOUNDS AND THEIR THERAPEUTIC USE | INSTITUTE OF CANCER RESEARCH ROYAL CANCER HOSPITAL (THE) (GB) | 2016-08-04 | — | — | US | disclosed |
| EP-3044221-A1 | 3-ARYL-5-SUBSTITUTED-ISOQUINOLIN-1-ONE COMPOUNDS AND THEIR THERAPEUTIC USE | Institute of Cancer Research: Royal Cancer Hospital (The) (GB) | 2016-07-20 | — | — | EP | disclosed |
| WO-2015036759-A1 | 3-ARYL-5-SUBSTITUTED-ISOQUINOLIN-1-ONE COMPOUNDS AND THEIR THERAPEUTIC USE | INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (THE) (GB) | 2015-03-19 | — | — | WO | disclosed |
| WO-2015036759-A1 | 3-ARYL-5-SUBSTITUTED-ISOQUINOLIN-1-ONE COMPOUNDS AND THEIR THERAPEUTIC USE | INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (THE) (GB) | 2015-03-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160221953-A1 | 3-ARYL-5-SUBSTITUTED-ISOQUINOLIN-1-ONE COMPOUNDS AND THEIR THERAPEUTIC USE | TNKS, TNKS2, PARP1 | TNKS 1/4885PARP1 3/4885CHKA 1145/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.